{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-23-003863","form_type":"8-K","ticker":"PHIO","cik":"0001533040","company_name":"Phio Pharmaceuticals Corp.","filed_at":"2023-06-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.293251+00:00","generated_at":"2026-06-14T08:10:38.928287+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Phio raises ~$4M in concurrent registered direct offering and private placement at $4.28/share","bullets":["Gross proceeds ~$4M; net proceeds ~$3.5M after fees; closed June 2, 2023.","Issued 233,646 shares in registered direct and 700,935 shares (or pre-funded warrants) in private placement at $4.28 each.","Issued Series A (5.5-yr term) and Series B (18-mo term) warrants to purchase up to 934,581 shares each at $4.03.","Proceeds to fund immuno-oncology programs, working capital, and general corporate purposes.","H.C. Wainwright acted as placement agent; received 7.5% cash fee and warrants to purchase 70,094 shares at $5.35."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-23-003863","json":"https://secwatch.observer/filing/0001683168-23-003863.json","markdown":"https://secwatch.observer/filing/0001683168-23-003863.md","text":"https://secwatch.observer/filing/0001683168-23-003863.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1533040/000168316823003863/0001683168-23-003863-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1533040/000168316823003863/phio_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T08:10:38.928287+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"191d136cab1df8c61ab9318a82d03387d6a7d46a","claim":"Phio Pharmaceuticals Corp. entered into Registered Direct Purchase Agreement with certain institutional and accredited investors valued at 233,646 shares of common stock at $4.28 per share; RD Series A and B warrants (effective 2023-05-31).","evidence_excerpt":"On May 31, 2023, Phio Pharmaceuticals Corp. (the “Company”) entered into a securities purchase agreement (the “Registered Direct Purchase Agreement”) with certain institutional and accredited investors in connection with a registered direct offering (the “Registered Direct Offering”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1533040/000168316823003863/0001683168-23-003863-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain institutional and accredited investors"},{"label":"Value","value":"233,646 shares of common stock at $4.28 per share; RD Series A and B warrants"},{"label":"Effective","value":"2023-05-31"}],"fact_type":"material_agreement"},{"claim_id":"47fbea201e5dbab1d2f50d8511b7877c02fe81f1","claim":"Phio Pharmaceuticals Corp. entered into Engagement Letter with H.C. Wainwright & Co., LLC with H.C. Wainwright & Co., LLC valued at Cash fee of 7.5% of gross proceeds; management fee of 1.0%; $60,000 for non-accountable expenses; $1 (effective 2023-01-20).","evidence_excerpt":"Pursuant to an engagement letter, dated as of January 20, 2023 (the “Engagement Letter”), between the Company and H.C. Wainwright & Co., LLC (the “Placement Agent”), the Company agreed to pay the Placement Agent a total cash fee equal to 7.5% of the gross proceeds received in the Registered Direct Offering and the PIPE Private Placement.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1533040/000168316823003863/0001683168-23-003863-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"H.C. Wainwright & Co., LLC"},{"label":"Value","value":"Cash fee of 7.5% of gross proceeds; management fee of 1.0%; $60,000 for non-accountable expenses; $1"},{"label":"Effective","value":"2023-01-20"}],"fact_type":"material_agreement"},{"claim_id":"ddc025aaf350bd9655de951b213d66e2af630e62","claim":"Phio Pharmaceuticals Corp. entered into PIPE Purchase Agreement with same institutional and accredited investors valued at 72,000 unregistered shares of common stock at $4.28 per share; pre-funded warrants; Series A and B w (effective 2023-05-31).","evidence_excerpt":"On May 31, 2023, the Company also entered into a securities purchase agreement (the “PIPE Purchase Agreement” and, together with the Registered Direct Purchase Agreement, the “Purchase Agreements”) and a registration rights agreement (the “Registration Rights Agreement”) with the same institutional and accredited investors in connection with a concurrent private placement (the “PIPE Private Placement”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1533040/000168316823003863/0001683168-23-003863-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"same institutional and accredited investors"},{"label":"Value","value":"72,000 unregistered shares of common stock at $4.28 per share; pre-funded warrants; Series A and B w"},{"label":"Effective","value":"2023-05-31"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}